Pearls for practice from the 2023 joint task force anaphylaxis practice parameter.
Curr Opin Pediatr
; 2024 Sep 04.
Article
en En
| MEDLINE
| ID: mdl-39254667
ABSTRACT
PURPOSE OF REVIEW To share important highlights on the management of anaphylaxis from the latest 2023 practice parameter. RECENT FINDINGS:
The 2023 Allergy Immunology Joint Task Force on Practice Parameters (JTFPP) anaphylaxis practice parameter provides updated anaphylaxis guidance. Criteria for the diagnosis of anaphylaxis are reviewed. The parameter highlights that while anaphylaxis is not more severe in younger children, age-specific symptoms can vary. Activation of emergency medical services may not be required in patients who experience prompt resolution of symptoms following epinephrine use and caregivers are comfortable with observation. For children weighing <15âkg, the anaphylaxis parameter suggests the clinician may prescribe either the 0.1âmg or the 0.15âmg epinephrine autoinjector, with the 0.3âmg autoinjector prescribed for those weighing 25âkg or greater. In patients with heart disease, discontinuing or changing beta blockers and/or angiotensin converting enzyme inhibitors may pose a larger risk for worsened cardiovascular disease compared with risk for severe anaphylaxis with medication continuation. Furthermore, in patients with a history of perioperative anaphylaxis, shared decision-making based on diagnostic testing and clinical history is recommended prior to repeat anesthesia use. Beyond the recent parameter update, novel contemporary therapies can decrease risk of community anaphylaxis.SUMMARY:
The 2023 JTFPP Anaphylaxis Guidelines offer up-to-date guidance for the diagnosis and management of anaphylaxis in infants, children, and adults.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Curr Opin Pediatr
Asunto de la revista:
PEDIATRIA
Año:
2024
Tipo del documento:
Article
Pais de publicación:
Estados Unidos